TCGA-22-1016-01A-01R-0692-07
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.430
- IL6_JAK_STAT3_SIGNALING+0.350
- TNFA_SIGNALING_VIA_NFKB+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- MYOGENESIS+0.290
- UV_RESPONSE_DN+0.260
- INFLAMMATORY_RESPONSE+0.220
- KRAS_SIGNALING_DN+0.220
- KRAS_SIGNALING_UP+0.220
- APICAL_SURFACE+0.170
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- GLYCOLYSIS-0.390
- MYC_TARGETS_V1-0.370
- DNA_REPAIR-0.340
- FATTY_ACID_METABOLISM-0.300
- PEROXISOME-0.290
- E2F_TARGETS-0.280
- MTORC1_SIGNALING-0.250
- MYC_TARGETS_V2-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-22-1002-01A-01R-0692-07 | — | cohortSQ1 | 0.880 |
| 2 | TCGA-55-7574-01A-11R-2039-07 | — | cohortMD2 | 0.879 |
| 3 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.877 |
| 4 | SRR975557 | — | — | 0.869 |
| 5 | TCGA-60-2715-01A-01R-0851-07 | — | cohortSQ1 | 0.868 |
| 6 | TCGA-56-8628-01A-11R-2403-07 | — | cohortSQ1 | 0.861 |
| 7 | 09f3976d-4e95-41b4-bc0b-27eea3e20bb3 | — | — | 0.860 |
| 8 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.858 |
| 9 | TCGA-98-A53H-01A-12R-A262-07 | — | cohortA1 | 0.856 |
| 10 | 0056507f-a296-4148-bc9f-a831249c7973 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.140 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |